NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Tivozanib

Dose level 1: 1.0mg for 21 days followed by 7 days rest; Dose level -1: 1.0mg every other day

DRUG

Durvalumab

1500mg every 28 days

Trial Locations (10)

Montefiore Medical Center, The Bronx

Roswell Park Cancer Institute, Buffalo

Northwestern University Feinberg School of Medicine, Chicago

UT Southwestern Medical Center, Dallas

The University of Texas Health Science Center at Tyler (UTHealth), Tyler

The University of Texas Health Science Center at Houston (UTHealth), Houston

Banner MD Anderson Cancer Center, Gilbert

City of Hope, Duarte

University of California - Irvine, Orange

Dana Farber Cancer Institute, Boston